Medivir strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant
Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB (“Medivir” or “the Company”) has renegotiated its agreement with TetraLogic Pharmaceuticals Corporation (”TetraLogic”) regarding financial obligations for birinapant, a SMAC mimetic, for the treatment of solid cancer tumors. The purpose of the new agreement is to create improved business development opportunities. Medivir acquired birinapant from TetraLogic in 2016. The original agreement between Medivir and TetraLogic included milestone payments with predetermined amounts as well as royalty obligations to